Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative-Reference-Cited by-同舟云学术

Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative

Published:2024-02-01 Issue: Volume: Page:
ISSN:0172-0643
Container-title:Pediatric Cardiology
language:en
Short-container-title:Pediatr Cardiol

Author:

Leone David M.^ORCID,Rodriguez Alexis,Cowenhoven Kirsten,O’Connell Matthew,Grossman Matthew,Ferdman Dina

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00246-023-03388-3.pdf

Reference23 articles.

1. AAoP Committee on Infectious Diseases, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, Respiratory Syncytial Virus, in Red Book: 2021–2024 Report of the Committee on Infectious Diseases. 2021, American Academy of Pediatrics. p. 0.

2. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM et al (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143(4):532–540. https://doi.org/10.1067/s0022-3476(03)00454-2

3. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA (1982) Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 307(7):397–400. https://doi.org/10.1056/NEJM198208123070702

4. Jung JW (2011) Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey. Korean J Pediatr 54(5):192–196. https://doi.org/10.3345/kjp.2011.54.5.192

5. Yamagishi H (2020) Respiratory Syncytial Virus Infection in Infants with Heart and Lung Diseases. Springer, Singapore